Rein Therapeutics Inc.
RNTX
$1.76
-$0.15-7.85%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 22.07% | 100.76% | 89.47% | 38.46% | 17.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 83.16% | 132.31% | 47.93% | -20.03% | -44.49% |
| Operating Income | -83.16% | -132.31% | -47.93% | 20.03% | 44.49% |
| Income Before Tax | -309.53% | -125.97% | -44.28% | 23.73% | 42.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -299.71% | -125.97% | -44.28% | 23.73% | 42.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -299.71% | -125.97% | -44.28% | 23.73% | 42.43% |
| EBIT | -83.16% | -132.31% | -47.93% | 20.03% | 44.49% |
| EBITDA | -84.18% | -133.42% | -48.40% | 20.03% | 44.58% |
| EPS Basic | -2.30% | -9.30% | 15.65% | 38.82% | 43.75% |
| Normalized Basic EPS | 42.52% | -18.04% | 10.80% | 35.60% | 47.11% |
| EPS Diluted | -2.30% | -9.30% | 15.65% | 38.82% | 43.77% |
| Normalized Diluted EPS | 42.52% | -18.04% | 10.80% | 35.60% | 47.11% |
| Average Basic Shares Outstanding | 289.11% | 200.83% | 106.58% | 21.96% | 1.30% |
| Average Diluted Shares Outstanding | 289.11% | 200.83% | 106.58% | 21.96% | 1.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |